Page 49 - GALENIKA MEDICAL JOURNAL

13. Abreu A, Frederix I, Dendale P, Janssen A, Doherty P, Piepoli MF, et al. 28. Burazor I, Cosic Z, Babic R, Otasevic P, Tasic N, Kostic S: Optimization
Secondary Prevention and Rehabilitation Section of EAPC Reviewers: of lipids for prevention in patients with documented atherosclerotic
Standardization and quality improvement of secondary prevention cardiovascular diseases. Our experiences. Atherosclerosis 2022, 353:
through cardiovascular rehabilitation programmes in Europe: The 254
avenue towards EAPC accreditation programme: A position statement
of the Secondary Prevention and Rehabilitation Section of the European 29. Bhatt DL, Steg PG, Miller M, Brinton EA, Jacobson TA, Ketchum SB, et al.
Association of Preventive Cardiology (EAPC). Eur J Prev Cardiol. 2021 REDUCE-IT Investigators. Cardiovascular Risk Reduction with Icosapent
May 14;28(5):496-509. Ethyl for Hypertriglyceridemia. N Engl J Med. 2019 Jan 3;380(1):11-22.
14. Andersson C, Johnson AD, Benjamin EJ, Levy D, Vasan RS. 70-year legacy 30. Kronenberg F, Mora S, Stroes ESG, Ference BA, Arsenault BJ, Berglund L,
of the Framingham Heart Study. Nat Rev Cardiol. 2019 Nov;16(11):687- et al. Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic
98. stenosis: a European Atherosclerosis Society consensus statement. Eur
Heart J. 2022 Oct 14;43(39):3925-46.
15. Dawber TR, Meadors GF, Moore FE Jr. Epidemiological approaches
to heart disease: the Framingham Study. Am J Public Health Nations 31. Marx N, Federici M, Schütt K, Müller-Wieland D, Ajjan RA, Antunes
Health. 1951 Mar;41(3):279-81. MJ, et al. ESC Scientific Document Group. 2023 ESC Guidelines for the
management of cardiovascular disease in patients with diabetes. Eur
16. Kannel WB, Dawber TR, Kagan A, Revotskie N, Stokes J 3rd. Factors of Heart J. 2023 Oct 14;44(39):4043-140.
risk in the development of coronary heart disease--six year follow-up
experience. The Framingham Study. Ann Intern Med. 1961 Jul;55:33-50. 32. Janković SM, Stojković S, Petrović M, Kostić T, Zdravković M, Radovanović
S, et al. Results of the trycort: Cohort study of add-on antihypertensives
17. Ho KK, Pinsky JL, Kannel WB, Levy D. The epidemiology of heart failure: for treatment of resistant hypertension. Medicine (Baltimore). 2023 Jun
the Framingham Study. J Am Coll Cardiol. 1993 Oct;22(4 Suppl A):6A- 2;102(22):e33941.
13A.
33. Koenig W. High-sensitivity C-reactive protein and atherosclerotic
18. Benjamin EJ, Levy D, Vaziri SM, D'Agostino RB, Belanger AJ, Wolf PA. disease: from improved risk prediction to risk-guided therapy. Int J
Independent risk factors for atrial fibrillation in a population-based Cardiol. 2013 Oct 15;168(6):5126-34.
cohort. The Framingham Heart Study. JAMA. 1994 Mar 16;271(11):840-4.
34. Kotseva K; EUROASPIRE Investigators. The EUROASPIRE surveys:
19. Kannel WB, Sorlie P, McNamara PM. Prognosis after initial myocardial lessons learned in cardiovascular disease prevention. Cardiovasc Diagn
infarction: the Framingham study. Am J Cardiol. 1979 Jul;44(1):53-9. Ther. 2017 Dec;7(6):633-9.
20. Brand FN, Larson M, Friedman LM, Kannel WB, Castelli WP. 35. De Bacquer D, Ueda P, Reiner Ž, De Sutter J, De Smedt D, Lovic D, et al.
Epidemiologic assessment of angina before and after myocardial EUROASPIRE IV and V National Coordinators. Prediction of recurrent
infarction: The Framingham study. Am Heart J. 1996 Jul;132(1 Pt 1):174- event in patients with coronary heart disease: the EUROASPIRE Risk
8. Model. Eur J Prev Cardiol. 2022 Mar 11;29(2):328-39.
21. De Vreede JJ, Gorgels AP, Verstraaten GM, Vermeer F, Dassen WR, 36. Hageman SHJ, McKay AJ, Ueda P, Gunn LH, Jernberg T, Hagström E, et
Wellens HJ. Did prognosis after acute myocardial infarction change al. Estimation of recurrent atherosclerotic cardiovascular event risk in
during the past 30 years? A meta-analysis. J Am Coll Cardiol. 1991 patients with established cardiovascular disease: the updated SMART2
Sep;18(3):698-706. algorithm. Eur Heart J. 2022 May 7;43(18):1715-27.
22. Wong ND, Wilson PW, Kannel WB. Serum cholesterol as a prognostic 37. Klooster CCV', Bhatt DL, Steg PG, Massaro JM, Dorresteijn JAN,
factor after myocardial infarction: the Framingham Study. Ann Intern Westerink J, et al. UCC-SMART study group. Predicting 10-year risk of
Med. 1991 Nov 1;115(9):687-93. recurrent cardiovascular events andcardiovascular interventions in
patients with established cardiovascular disease: results from UCC-
23. Jernberg T, Hasvold P, Henriksson M, Hjelm H, Thuresson M, Janzon SMART and REACH. Int J Cardiol. 2021 Feb 15;325:140-8.
M. Cardiovascular risk in post-myocardial infarction patients:
nationwide real world data demonstrate the importance of a long-term 38. Castelijns MC, Helmink MAG, Hageman SHJ, Asselbergs FW, de Borst GJ,
perspective. Eur Heart J. 2015 May 14;36(19):1163-70. Bots ML, et al. Cohort profile: the Utrecht Cardiovascular Cohort-Second
Manifestations of Arterial Disease (UCC-SMART) Study-an ongoing
24. Fox KA, Carruthers KF, Dunbar DR, Graham C, Manning JR, De Raedt H, prospective cohort study of patients at high cardiovascular risk in the
et al. Underestimated and under-recognized: the late consequences of Netherlands. BMJ Open. 2023 Feb 20;13(2):e066952.
acute coronary syndrome (GRACE UK-Belgian Study). Eur Heart J. 2010
Nov;31(22):2755-64. 39. Kaasenbrood L, Bhatt DL, Dorresteijn JAN, Wilson PWF, D'Agostino RB
Sr, Massaro JM, et al. Estimated Life Expectancy Without Recurrent
25. Bhatt DL, Eagle KA, Ohman EM, Hirsch AT, Goto S, Mahoney EM, et al. Cardiovascular Events in Patients With Vascular Disease: The SMART-
REACH Registry Investigators. Comparative determinants of 4-year REACH Model. J Am Heart Assoc. 2018 Aug 21;7(16):e009217.
cardiovascular event rates in stable outpatients at risk of or with
atherothrombosis. JAMA. 2010 Sep 22;304(12):1350-7.
26. Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon Declaration of interest statement: None
L, et al. ESC Scientific Document Group. 2019 ESC/EAS Guidelines
for the management of dyslipidaemias: lipid modification to reduce Received: 05. 02. 2024.
cardiovascular risk. Eur Heart J. 2020 Jan 1;41(1):111-88.
Accepted: 19. 02. 2024.
27. Ray KK, Molemans B, Schoonen WM, Giovas P, Bray S, Kiru G, et al. DA Online: 31. 03. 2024.
VINCI study. EU-Wide Cross-Sectional Observational Study of Lipid-
Modifying Therapy Use in Secondary and Primary Care: the DA VINCI
study. Eur J Prev Cardiol. 2021 Sep 20;28(11):1279-89.

REVIEW PAPER Galenika Medical Journal, 2024; 3(9):42-47. 47